MCL1 Inhibitor Combination Therapy for the Treatment of Melanoma

Melanoma causes the majority of skin cancer related deaths in the US despite only accounting for 1% of skin cancer cases. Immunotherapy has improved survival for melanoma patients, however 50% of these individuals will be refractory to first line treatment. Dr. Shellman and her team at the University of Colorado have identified a MCL1 inhibitor-immunotherapy combination therapy that may be effective in treatment resistant and refractory melanoma. In addition, uveal melanoma is identified as a particularly susceptible melanoma subtype to MCL1 inhibitor alone due to their unique expression of BFL1 and PUMA.
Download Summary Document Here:
For Information, Contact:
Doreen Molk
University of Colorado
Yiqun Shellman
Richard Tobin
David Norris
Disease Areas:
For inquiries, email:     © 2024. All Rights Reserved. Powered by Inteum